During the period of 1985, Simon Campbell of Pfizer Sandwich Company in Britain and others planned to reduce blood pressure by developing drugs that can increase the antihypertensive factor atrial natriuretic peptide (ANP).
1989, Andrew Bell and others started from zaplaster, a PDE inhibitor with low activity, and synthesized a small molecular substance UK-92,480, which was 100 times higher than the original compound, and thought that it could inhibit PDE5, and applied for a patent.
However, Ian Osterloh, who is in charge of clinical research, and others have observed that taking drugs by volunteers will produce "side effects" of penile erection.
After understanding these studies, Pfizer's research team linked NO to the side effects of UK-92480.
After the study, it was found that inhibition of PDE5 would transform cGMP into GMP, and the GMP level would increase until the blood vessels dilated and the blood volume increased, so that ed could be treated.
The clinical trial * * * involved more than 300 people and achieved great success. Market research also gave positive results, so Peter Dunn and others worked out a new synthesis method through research. 1996, this product was patented for synthesis and new indications, named sildenafil.
Due to pulmonary hypertension, which can lead to right heart failure, PDE5 inhibitors can also be used for treatment. The FDA approved the indication of sildenafil in the treatment of pulmonary hypertension in 2005. But the trade name is Revatio.
In 2008, the sales of sildenafil reached $654.38+0.9 billion. In 20 13, Pfizer announced that it would sell the product directly to patients online.